KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Novavax (NVAX) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to 0.37%.

  • Novavax's Return on Capital Employed rose 8900.0% to 0.37% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.37%, marking a year-over-year increase of 8900.0%. This contributed to the annual value of 0.47% for FY2024, which is 9700.0% up from last year.
  • According to the latest figures from Q3 2025, Novavax's Return on Capital Employed is 0.37%, which was up 8900.0% from 0.38% recorded in Q2 2025.
  • Novavax's Return on Capital Employed's 5-year high stood at 64.22% during Q1 2023, with a 5-year trough of 35.67% in Q2 2023.
  • In the last 5 years, Novavax's Return on Capital Employed had a median value of 0.68% in 2024 and averaged 0.14%.
  • As far as peak fluctuations go, Novavax's Return on Capital Employed surged by 670700bps in 2023, and later crashed by -647400bps in 2024.
  • Over the past 5 years, Novavax's Return on Capital Employed (Quarter) stood at 9.32% in 2021, then surged by 135bps to 3.27% in 2022, then plummeted by -288bps to 6.15% in 2023, then surged by 92bps to 0.52% in 2024, then soared by 172bps to 0.37% in 2025.
  • Its Return on Capital Employed stands at 0.37% for Q3 2025, versus 0.38% for Q2 2025 and 0.41% for Q1 2025.